Clinical trials: Cancer of Breast
Breast Cancer
Study of Nivolumab Versus Placebo in Combination With Neoadjuvant Chemotherapy and Adjuvant Endocrine Therapy in Participants With High-risk, Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Primary Breast Cancer
A randomized multi-arm study evaluating the efficacy and safety of nivolumab versus placebo in combination with neoadjuvant (pre-surgery) chemotherapy and adjuvant (post-surgery) endocrine therapy in participants with high-risk…
- Trial name
- CheckMate 7FL (NCT04109066)
- Testing
- nivolumab, paclitaxel (PTX), anthracycline
- Where
- 240 sites in United States, Argentina and 30 more
- Volunteers
- 521 people
- Sponsor
- Bristol-Myers Squibb
Recurrent Breast Cancer, Metastatic Breast Cancer
Ruxolitinib W/ Preop Chemo For Triple Negative Inflammatory Brca
This phase I/II research study is evaluating a combination of drugs called paclitaxel and ruxolitinib as a possible treatment for inflammatory breast cancer.
- Trial name
- NCT02041429
- Testing
- Ruxolitinib, Paclitaxel
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Dana-Farber Cancer Institute
Breast Neoplasms
Regional Anesthesia and Breast Cancer Recurrence
In this multi-center trial, Stage 1-3 patients having mastectomies or isolated lumpectomy with axillary node dissection will be randomly assigned to thoracic epidural or paravertebral anesthesia/analgesia, or to general…
- Trial name
- NCT00418457
- Testing
- General anesthesia and opioids, Regional analgesia and propofol
- Where
- 6 sites in United States, Austria and 4 more
- Volunteers
- 2,108 people
- Sponsor
- The Cleveland Clinic
Recurrent Breast Carcinoma, Stage IIIB Breast Cancer
Akt Inhibitor MK2206 in Treating Patients With Advanced Breast Cancer
This phase II trial studies how well Akt inhibitor MK2206 works in treating patients with breast cancer cancer that has spread to other places in the body and usually cannot be cured or controlled with treatment.
- Conditions
- Recurrent Breast Carcinoma, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
- Trial name
- NCT01277757
- Testing
- Akt Inhibitor MK2206, Laboratory Biomarker Analysis, Pharmacological Study
- Where
- 5 sites in United States
- Volunteers
- 30 people
- Sponsor
- National Cancer Institute (NCI)
CIPN - Chemotherapy-Induced Peripheral Neuropathy
The CONTRoL Trial: Cryotherapy vs. cOmpression Neuropathy TRiaL
The primary objective of this study is to select the best intervention from cold therapy, compression therapy and placebo at reducing neuropathic pain as measured by the change in the Neurotoxicity (NTX) component of the…
- Trial name
- CONTRoL (NCT03873272)
- Testing
- Cryotherapy, Compression Therapy, Loose glove/sock
- Where
- United States
- Volunteers
- 63 people
- Sponsor
- Columbia University
Breast Cancer
Bioprosthetic Mesh to Expand the Lower Pole in Tissue Expander Reconstruction
The goal of this clinical research study is to learn if the complication rate and post-surgical appearance differ based on what type of mesh is used for breast reconstruction surgery.
- Trial name
- NCT01310075
- Testing
- Alloderm, Surgimend
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer
Study of Faslodex +/- Concomitant Arimidex v Exemestane Following Progression on Non-steroidal Aromatase Inhibitors
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using fulvestrant, anastrozole, or exemestane may fight breast cancer by blocking the use of estrogen by the tumor cells or by lowering the amount…
- Trial name
- SoFEA (NCT00253422)
- Testing
- Anastrozole, Exemestane, Fulvestrant
- Where
- 2 sites in United Kingdom
- Volunteers
- 698 people
- Sponsor
- Institute of Cancer Research, United Kingdom
Breast Cancer
A Study of Rucaparib Administered With Radiation in Patients With Triple Negative Breast Cancer With an Incomplete Response Following Chemotherapy
The purpose of this study is to test the safety of a study drug called Rucaparib, administered in combination with the type of radiation therapy that is usually given to women with your form of breast cancer.
- Trial name
- NCT03542175
- Testing
- Rucaparib, Radiotherapy
- Where
- 8 sites in United States
- Volunteers
- 31 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Early-Stage Breast Cancer
Proton Therapy for Early Stage Breast Cancer
The purpose of this study is to determine if partial breast proton therapy is effective treatment for early stage breast cancer following lumpectomy.
- Trial name
- NCT00614172
- Testing
- Proton radiation therapy
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- Loma Linda University
Breast Cancer
Phase 2 Study of Lovastatin as Breast Cancer Chemoprevention
The study evaluates if a 6-month course of oral lovastatin at 80 mg/day would decrease abnormal breast duct cytology in women with a high inherited breast cancer risk.
- Trial name
- NCT00285857
- Testing
- Lovastatin
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Stanford University
Breast Carcinoma
Cryotherapy for the Prevention of Taxane-Induced Sensory Neuropathy of the Hands and Feet in Breast Cancer Patients
This clinical trial investigates the effect and tolerability of cryotherapy and to evaluate whether they can prevent or improve taxane-induced sensory peripheral neuropathy in breast cancer patients.
- Trial name
- NCT04256512
- Testing
- Medical Device Usage and Evaluation, Questionnaire Administration
- Where
- United States
- Volunteers
- 94 people
- Sponsor
- Mayo Clinic
Breast Neoplasms, Breast Cancer
Eribulin Mesylate Phase IV Clinical Trial in Korean Patients With Metastatic or Locally Advanced Breast Cancer
This clinical study is designed as an open, single group, multi-center, phase 4 clinical study to assess the safety of eribulin which is approved for the treatment of the patients in Korea with locally advanced or metastatic…
- Trial name
- ESKIMO (NCT01961544)
- Testing
- Eribulin mesylate
- Where
- 14 sites in South Korea
- Volunteers
- 101 people
- Sponsor
- Eisai Korea Inc.
Recurrent Breast Cancer, Stage IV Breast Cancer
Sorafenib and Anastrozole in Treating Postmenopausal Women With Metastatic Breast Cancer
Sorafenib may stop the growth of tumor cells by blocking blood flow to the tumor and by blocking some of the enzymes needed for cell growth. Estradiol can cause the growth of breast cancer.
- Trial name
- NCT00217399
- Testing
- sorafenib tosylate, anastrozole
- Where
- United States
- Volunteers
- 35 people
- Sponsor
- National Cancer Institute (NCI)
Breast Carcinoma, Estrogen Receptor Positive
68-Ga-RM2 PET/MRI in Imaging Patients With Estrogen Receptor-Positive Breast Cancer
This trial studies how well 68-Ga RM2 works with PET/MRI in imaging patients with estrogen receptor-positive breast cancer. 68-Ga-RM2 is an agent used in diagnostic imaging.
- Trial name
- NCT03831711
- Testing
- Gallium Ga 68-labeled GRPR Antagonist BAY86-7548, Magnetic Resonance Imaging, Positron Emission Tomography
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- Andrei Iagaru
Breast Cancer, Breast Cancer - Female
TEEL Study- Phase 1 Tamoxifen and Ribociclib (LEE011) in Advanced ER+ (HER2 Negative) Breast Cancer
The purpose of this study is to find out if the investigational drug Ribociclib (LEE011), when taken with standard treatment (Tamoxifen +/- Goserelin) is safe and has beneficial effects in pre-menopausal and post-menopausal women…
- Conditions
- Breast Cancer, Breast Cancer - Female, Breast Cancer - Male
- Trial name
- NCT02586675
- Testing
- Tamoxifen, Ribociclib, Goserelin
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Invasive Breast Carcinoma, Triple-Negative Breast Carcinoma
Liposomal Doxorubicin, Bevacizumab, and Everolimus in Patients With Locally Advanced TNBC With Tumors Predicted Insensitive to Standard Chemotherapy; A Moonshot Initiative
This phase II trial studies how well pegylated liposomal doxorubicin, bevacizumab, and everolimus work in treating patients with triple-negative breast cancer with tumors predicted insensitive to standard chemotherapy.
- Trial name
- NCT02456857
- Testing
- Bevacizumab, Everolimus, Laboratory Biomarker Analysis
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer
Surgery to Remove Sentinel Lymph Nodes With or Without Removing Lymph Nodes in the Armpit in Treating Women With Breast Cancer
RATIONALE: Removing the sentinel lymph nodes and examining them under a microscope may help plan more effective surgery for breast cancer.
- Trial name
- NCT00003830
- Testing
- conventional surgery, Sentinel node resection followed by node examination
- Where
- 78 sites in United States, Canada and 1 more
- Volunteers
- 5,611 people
- Sponsor
- NSABP Foundation Inc
Breast Neoplasms
Study to Assess The Efficacy and Safety of a PARP Inhibitor For The Treatment of BRCA-positive Advanced Breast Cancer
The purpose of the study is to see if the drug KU-0059436 (olaparib) is effective and well tolerated in treating participants with measurable breast cancer gene (BRCA)1- or BRCA2-positive advanced breast cancer and for whom no…
- Trial name
- ICEBERG 1 (NCT00494234)
- Testing
- Olaparib
- Where
- 17 sites in United States, Australia and 6 more
- Volunteers
- 54 people
- Sponsor
- AstraZeneca
Male Breast Cancer, Recurrent Breast Cancer
ONTAK® in Treating Patients With Advanced Breast Cancer That Did Not Respond to Previous Treatment
RATIONALE: ONTAK may be able to help reduce the type of cells that prevent other types of immune cells from attacking the breast cancer cells.
- Conditions
- Male Breast Cancer, Recurrent Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer
- Trial name
- NCT00425672
- Testing
- ONTAK, flow cytometry, immunohistochemistry staining method
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- University of Washington
Breast Cancer
Phase III to Evaluate Patient´s Preference of Subcutaneous Trastuzumab vs Intravenous in HER2+ Advanced Breast Cancer
GEICAM/2012-07 is a study phase III, prospective, open, randomized, multicenter and national designed to assess patient preference for intravenous (IV) or subcutaneous (SC) of trastuzumab, and within the SC by the administration…
- Trial name
- ChangHER-SC (NCT01875367)
- Testing
- Trastuzumab Injectable Solution, Trastuzumab Injectable Product, Trastuzumab Injection
- Where
- 27 sites in Spain
- Volunteers
- 166 people
- Sponsor
- Spanish Breast Cancer Research Group
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.